Cost-effectiveness of stroke treatments and secondary preventions (Q38020935)

27 August 2017

title

Cost-effectiveness of stroke treatments and secondary preventions (English)

1 reference

27 August 2017

Feng Pan

1

1 reference

27 August 2017

Luis Hernandez

series ordinal

2

1 reference

27 August 2017

Alex Ward

series ordinal

3

1 reference

27 August 2017

language of work or name

English

0 references

publication date

24 June 2012

1 reference

Expert Opinion on Pharmacotherapy

27 August 2017

published in

1 reference

27 August 2017

volume

13

1 reference

27 August 2017

issue

12

1 reference

27 August 2017

page(s)

1751-1760

1 reference

Heart disease and stroke statistics--2011 update: a report from the American Heart Association

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Model-based cost-effectiveness analyses for the treatment of acute stroke events: a review and summary of challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Development of a decision-analytic model of stroke care in the United States and Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Trial application of a Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS) to assist priority setting in stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Development and application of Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS): an Australian economic model for stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

The Economic Case for New Stroke Thrombolytics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Estimated cost savings of increased use of intravenous tissue plasminogen activator for acute ischemic stroke in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Efficacy and costs of secondary prevention with antiplatelets after ischaemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/Asasantin) in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

Making Decisions About Antithrombotic Therapy in Heart Disease: Decision Analytic and Costeffectiveness Issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699522

10.1517/14656566.2012.699522

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference